Panelists discuss how the SUNLIGHT trial’s demonstration that adding bevacizumab to trifluridine/tipiracil improves overall survival and progression-free survival represents the best available data in refractory colorectal cancer, with quality of life findings showing longer time to definitive deterioration being particularly significant for patient counseling since patients in third-line and beyond settings prioritize both survival benefit and maintaining good quality of life, making this combination compelling as it provides efficacy improvement without dramatically compromising patient well-being.